Literature DB >> 3283297

Histocompatibility antigens in multiple sclerosis patients participating in a multicentre trial of azathioprine. British & Dutch Multiple Sclerosis Azathioprine Trial Group.

.   

Abstract

The human leucocyte antigen (HLA) types of 283 patients with multiple sclerosis participating in a trial of azathioprine treatment were studied. The prevalence of HLA types was compared with those of over 3,300 controls from tissue typing centres in the UK. The prevalence of HLA A3 (38.5% cp 26.1%), HLA B7 (44.9% cp 27.3%) and HLA DR2 (58.3% cp 30.6%) was increased in the multiple sclerosis patients compared with the controls. Age at onset, disease status (relapsing-remitting or currently progressive) and disease severity did not show an association with any particular HLA type.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3283297      PMCID: PMC1032869          DOI: 10.1136/jnnp.51.3.412

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  11 in total

1.  MICRODROPLET ASSAY OF HUMAN SERUM CYTOTOXINS.

Authors:  P I TERASAKI; J D MCCLELLAND
Journal:  Nature       Date:  1964-12-05       Impact factor: 49.962

2.  FURTHER NOTES ON DISABILITY EVALUATION IN MULTIPLE SCLEROSIS, WITH SCALE MODIFICATIONS.

Authors:  J F KURTZKE
Journal:  Neurology       Date:  1965-07       Impact factor: 9.910

3.  The distribution of multiple sclerosis in the United Kingdom.

Authors:  R J Swingler; D Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-10       Impact factor: 10.154

4.  A double-blind trial of transfer factor vs placebo in multiple sclerosis patients.

Authors:  R C Collins; L R Espinoza; C R Plank; G C Ebers; R A Rosenberg; J B Zabriskie
Journal:  Clin Exp Immunol       Date:  1978-07       Impact factor: 4.330

5.  Histocompatibility determinants in multiple sclerosis, with special reference to clinical course.

Authors:  C Jersild; T Fog; G S Hansen; M Thomsen; A Svejgaard; B Dupont
Journal:  Lancet       Date:  1973-12-01       Impact factor: 79.321

6.  Double-blind controlled trial of immunosuppression in the treatment of multiple sclerosis: final report.

Authors:  J Mertin; P Rudge; M Kremer; M J Healey; S C Knight; A Compston; J R Batchelor; E J Thompson; A M Halliday; M Denman; P B Medawar
Journal:  Lancet       Date:  1982-08-14       Impact factor: 79.321

7.  Multiple sclerosis and HLA DQw1.

Authors:  D A Francis; J R Batchelor; W I McDonald; J E Hern; A W Downie
Journal:  Lancet       Date:  1986-01-25       Impact factor: 79.321

8.  HLA profiles in multiple sclerosis suggest two forms of disease and the existence of protective haplotypes.

Authors:  M Madigand; J J Oger; R Fauchet; O Sabouraud; B Genetet
Journal:  J Neurol Sci       Date:  1982-03       Impact factor: 3.181

9.  Genetic basis of multiple sclerosis: HLA antigens, disease progression, and oligoclonal IgG in CSF.

Authors:  L Stendahl-Brodin; H Link; E Möller; E Norrby
Journal:  Acta Neurol Scand       Date:  1979-06       Impact factor: 3.209

10.  HLA antigens and progression of multiple sclerosis. Part II.

Authors:  L Dejaegher; M de Bruyere; P Ketelaer; H Carton
Journal:  J Neurol       Date:  1983       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.